ArticleAmerican journal of translational research2017
MicroRNA-423 enhances the invasiveness of hepatocellular carcinoma via regulation of BRMS1.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- EIF4A3-Mediated downregulation of circPTEN promotes hepatocellular carcinoma progression through the miR-1289/RBM38 Axis.Journal of molecular histology · 2025Article
- BRMS1 in Gliomas-An Expression Analysis.Cancers · 2023Article
- Overexpression of LINC00607 inhibits cell growth and aggressiveness by regulating the miR-1289/EFNA5 axis in non-small-cell lung cancer.Open medicine (Warsaw, Poland) · 2023Article
- Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.World journal of gastroenterology · 2022Article
- Circ_0092291 attenuates angiotensin II-induced cell damages in human aortic vascular smooth muscle cells via mediating the miR-626/COL4A1 signal axis.Journal of physiology and biochemistry · 2022Article
- Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma.Journal of cellular and molecular medicine · 2022Review
- Functional mechanism and clinical implications of MicroRNA-423 in human cancers.Cancer medicine · 2020Review
- BRMS1: a multifunctional signaling molecule in metastasis.Cancer metastasis reviews · 2020Review
- Article
- Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses.Molecular medicine reports · 2019Article
- Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma.Scientific reports · 2019Article
- MicroRNAs contribute to ATP-binding cassette transporter- and autophagy-mediated chemoresistance in hepatocellular carcinoma.World journal of hepatology · 2019Review
- miR-455 Functions as a Tumor Suppressor Through Targeting GATA6 in Colorectal Cancer.Oncology research · 2019Article
- Serum miR-626 and miR-5100 are Promising Prognosis Predictors for Oral Squamous Cell Carcinoma.Theranostics · 2019Article
- Low expression of LACTB promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma.American journal of translational research · 2018Article
- MiRNA Polymorphisms and Cancer Prognosis: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor metastasis portrayed the most serious challenges of cancer as it is the major cause of mortality in patients with solid tumors, including hepatocellular carcinoma (HCC). In this regard, anti-metastatic genes have a great potential for metastasis inhibition. Recent evidence pointed to a role of Breast cancer metastasis suppressor 1 (BRMS1) in suppression of metastasis of several types of cancers, whereas the regulation of BRMS1 in HCC remains unknown. Here, we used bioinformatics analyses to predict BRMS1-targeting microRNAs (miRNAs), and evaluated the functional binding of miRNAs to BRMS1 mRNA using a dual luciferase reporter assay. Among all BRMS1-targeting miRNAs, we only detected significant expression of miR-626, miR-1289 and miR-423 in HCC specimens. Specifically, we found that only miR-423 significantly inhibited protein translation of BRMS1 via specific binding to 3'-UTR of the BRMS1 mRNA. Moreover, we detected significantly lower levels of BRMS1 and significantly higher levels of miR-423 in the HCC specimens, relative to paired adjacent non-tumor liver tissue. Furthermore, BRMS1 and miR-423 levels were correlated inversely. Overexpression of miR-423 significantly decreased BRMS1 levels and promoted HCC cell invasion, while depletion of miR-423 significantly increased BRMS1 levels and inhibited HCC cell invasion. This study sheds light on miR-423 as a crucial factor that enhances HCC cell invasiveness, and suggests miR-423 as a promising therapeutic target for HCC treatment.
Indexed as
Identifiers
29312509PMC5752907W3022376142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.